About Linc
Linc is a venture capital firm founded in 1991. It is primarily based out of Stockholm, Sweden. As of Jul 2025, Linc has invested in 20 companies. It primarily invests in Post IPO round in Sweden based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and FinTech. Most recently it participated in the $***** Post IPO round of OncoZenge Overall, Linc portfolio has seen 9 IPOs including key companies like Cinclus Pharma, OssDsign and Calliditas Therapeutics. A lot of funds co-invest with Linc, with names like Trill impact sharing a substantial percentage of its portfolio. Linc has team of 5 people including 3 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Rounds of Entry
Post IPO, Series A & 1 more
Portfolio IPOs
Linc's List of Top Investments
Linc has a portfolio of 20 companies. Their most notable investmentis in Akiram TherapeuticsTheir portfolio spans across Sweden, Denmark and United States. They have invested in Life Sciences, High Tech, FinTech and 7 other sectors, across stages such as Post IPO, Series A and 1 more. Here is the list of top investments by Linc:
Developer of small molecules for the treatment of gastric acid-related diseases. The lead candidate of the company is Linaprazan glurate a potassium-competitive acid blocker (P-CAB) and a prodrug of linaprazan for the treatment of erosive Gastroesophageal reflux disease (eGERD).
Key facts about Cinclus Pharma
- Founded Year: 2014
- Location: Gothenburg (Sweden)
- Stage: Public
- Total Funding till date: $25.7M
- Employee Count: 27 as on Sep 30, 2026
- Investors: Fjarde AP-fonden, Irrus Investments and 6 Others
- Latest Funding Round: Series B, Apr 19, 2022, $*****
- Highlight: Public
2. OssDsign
Developer of regenerative 3D-printed orthopedic implants for craniofacial bone defects and trauma. Its implants incorporate a proprietary calcium phosphate-based material composition, reinforced by titanium, and CAD-based manufacturing and design. It uses 3D printing technologies to produce implants using materials like titanium combined with cured ceramic tiles. Its products have applications in the reconstruction of facial bone after trauma, tumor resection or growth retardation due to irradiation, and the repair of hereditary facial defects such as paranasal augmentation in cleft patients and correction of hemifacial microsomia.
Key facts about OssDsign
- Founded Year: 2011
- Location: Uppsala (Sweden)
- Stage: Public
- Total Funding till date: $19.7M
- Employee Count: 47 as on Sep 30, 2026
- Investors: SEB, Eiffel Investment Group and 11 Others
- Latest Funding Round: Post IPO, Jun 04, 2025, $*****
- Highlight: Public
Gesynta Pharma is developing oral therapies for treating chronic inflammatory conditions. The lead candidate of the company GS-248 is used for treating niche inflammatory indications. It's in the preclinical stage. It acts by inhibiting selective mPGES-1(microsomal prostaglandin E-synthase-1).
Key facts about Gesynta Pharma
- Founded Year: 2017
- Location: Solna (Sweden)
- Stage: Series B
- Total Funding till date: $31.1M
- Employee Count: 24 as on Sep 30, 2026
- Investors: Hadean Ventures, Industrifonden and 2 Others
- Latest Funding Round: Series B, Sep 16, 2020, $*****
- Highlight: Editors' Pick
4. FluoGuide
Developer of surgery targeting drugs for cancer patients. The lead product FG001 contains a fluorophore that is injected into the patient’s vein prior to surgery binds to cancer cells expressing a marker of cancer uPAR and lights up cancer cells and their invasive growth into the surrounding tissue.
Key facts about FluoGuide
Calliditas Therapeutics is involved in the development of small molecule-based drugs for inflammatory kidney diseases. Its leading candidate Nefecon is used in inflammatory kidney disease (IgA nephropathy) for the patients at risk of progressing to renal failure. It releases Budesonide, a Glucocorticosteroid, in the lower ileum and ascending colon of the gastrointestinal (GI) tract. The targeted release of the active ingredient to this region of the GI tract will bypass the systemic side effects of budesonide. The company has also discovered potential uses of this formulation for autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC).
Key facts about Calliditas Therapeutics
- Founded Year: 2004
- Location: Stockholm (Sweden)
- Stage: Public
- Total Funding till date: $44.8M
- Employee Count: 154 as on Sep 30, 2026
- Investors: Athyrium Capital Management, Industrifonden and 3 Others
- Latest Funding Round: Series B, Jul 2019, $*****
- Highlight: Public
Linc's Year-on-Year Investment Trends
Linc has invested in 20 companies over the last 11 years, with an average of 0 new investment annually in the last 10 years. In 2025, it made 2 investments. Its most recent first time investment was in OncoZenge and most recent follow-on round was in OssDsign.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 1 | 1 | 2 |
2024 | 0 | 0 | 0 |
2023 | 2 | 0 | 2 |
2022 | 1 | 0 | 1 |
Linc's Investments by Stage
Linc has made 2 investments in Post IPO stage with an average round size of $7.19M, 2 investments in Series A stage with an average round size of $4.63M and 1 investment in Series B stage.Stage of entry | No. of Investments |
|---|---|
Post IPO | 2 |
Series A | 2 |
Series B | 1 |
Note: We have considered here, only first round of investments
Linc's Investments by Sector
Linc has a diverse portfolio, with companies operating in the Life Sciences and High Tech. Notably, it has invested in 13 Enterprise (B2B) companies, 10 Tech companies, 1 Consumer (B2C) company and at least 1 company focusing on Marketplace.Sector | No. of Investments |
|---|---|
Life Sciences | 5 |
High Tech | 1 |
Note: We have considered here, only first round of investments
Linc's Investments by Geography
Linc has made most investments in Sweden (5).Linc's recent investments
Linc has not made any investment in 2026 so far.Here are the most recent investments by Linc:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jul 09, 2025 | Sweden | Post IPO | 4811 | - | |
Jun 04, 2025 | Sweden | Post IPO | 1991 | [+2] | |
Sep 27, 2023 | Sweden | Post IPO | 4051 | ||
Jan 12, 2023 | Sweden | Series A | 8346 | ||
Apr 19, 2022 | Sweden | Series B | 7676 | [+3] |
IPOs and Publicly Listed companies in Linc's Portfolio
9 of Linc's portfolio companies have become public. Cinclus Pharma got listed on the Stockholm Stock Exchange (STO), in Jun 2024 at marketcap of $105M and OncoZenge got listed on the Stockholm Stock Exchange (STO).Here are Linc's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 20, 2024 | Apr 19, 2022 | Series B | 1795 | |
Feb 12, 2021 | Jul 09, 2025 | Post IPO | 3274 | |
Jun 11, 2020 | - | - | 7447 | |
May 24, 2019 | Sep 27, 2023 | Post IPO | 2446 | |
Jun 21, 2017 | - | - | 7538 |
Team profile of Linc
Linc has a team of 5 members including 3 Partners located in Sweden. Linc's team sits on the board of 1 company.Here is a list of all team members in Linc:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Stockholm | - | - | |
Partner | Sweden | - | ||
Partner | Sweden | - | - |
Co-investors of Linc
Over the past 11 years, 18 investors have co-invested in Linc's portfolio companies. This includes funds and angels.
- Invested before Linc: Karolinska Development, Fjarde AP-fonden and 7 others have invested in rounds before Linc. There are 2 companies where Karolinska Development has invested before Linc and 1 company where Fjarde AP-fonden has invested before Linc.
- Top Co-investors of Linc: 6 investors entered a company along with Linc. These include investors like Trill impact (1 company).
- Invested after Linc: A total of 3 investors have invested in Linc's portfolio after their investments. Top Investors include Adrigo (1 company), La Financiere de l Echiquier (1 company) and Lancelot (1 company).
Recent News related to Linc
•
OncoZenge Secures SEK 7.5 Million Convertible Loan Agreement with Linc ABCision•Jul 09, 2025•OncoZenge, Linc
•
BerGenBio ASA Announces Fully Underwritten Rights Issue to Raise Approximately NOK 130 MillionCision•Jul 01, 2025•BerGenBio, Oncoinvent, ABG Sundal Collier, DNB and 4 others
•
Announcement of fully underwritten rights issuePR Newswire•Jul 01, 2025•BerGenBio, Oncoinvent, ABG Sundal Collier, DNB and 4 others
•
BerGenBio announces fully underwritten rights issue for NOK 130 million after Oncoinvent ASA mergerDagens industri•Jul 01, 2025•Hadean Ventures, Linc, BerGenBio, Oncoinvent
•
Gesynta Pharma Receives $27 M For Endometriosis Novel Therapy DrugForbes•Feb 13, 2025•Gesynta Pharma, Innovestor, Amboy Street Ventures, Foreground Capital and 18 others
•
Karolinska Development divests 4,6 million shares in portfolio company OssDsignGlobeNewswire•Dec 11, 2024•Karolinska Development, OssDsign, Linc
•
•
Swedish biotech announces its closing of €22M private placement to further its commercialization strategyArcticStartup•May 24, 2022•Linc, Eir Ventures, Trill impact, Cinclus Pharma
